CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for GRAIL Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

GRAIL Inc
1525 O'Brien Drive
Phone: (650) 771-9796p:650 771-9796 MENLO PARK, CA  94025  United States Fax: (302) 655-5049f:302 655-5049
Business Summary
GRAIL Inc is a United States-based healthcare company. The Company focuses on developing new technologies for early cancer detection. By leveraging it's platform technology, the Company has developed a multi-cancer early detection blood test that has the ability to detect more than 50 types of cancer, across all stages, and localize the cancer signal from a single blood draw. The Company has developed multi-cancer early detection test, Galleri, which is designed as a screening test for asymptomatic individuals over 50 years of age. In addition to Galleri, the Company is utilizing it's technology platform and population-scale studies to introduce a diagnostic aid for cancer test (DAC). DAC is designed to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing a minimal residual disease (MRD) test, designed to enable blood-based detection with or without tissue.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202012/31/2019YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2835 In vitro and in vivo diagnostic substances
8071 Medical laboratories

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chair of the Board of Directors Catherine J.Friedman 61 12/1/2019 12/14/2017
Chief Executive Officer, Director Hans E.Bishop 56 12/1/2019 8/9/2018
Vice Chairman of the Board, Founding Chief Executive Officer Jeffrey T.Huber 53 12/1/2019
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Grail (BVI) Limited
Grail Bio UK Limited
Grail Hong Kong Limited
Grail Limited

General Information
Outstanding Shares: 135,851,866 (As of 9/17/2020)
Federal Tax Id: 475117880
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 31, 2023